Stopping MK-677: What Studies Report About Discontinuation

Why "what happens after stopping" is hard to answer from the literature

Searches about MK-677 (also written MK-0677 or ibutamoren) after cessation are common, but the peer-reviewed record was not built to answer them. Most published work on this growth hormone secretagogue examined what happened during administration: hormone changes, body composition, disease outcomes or analytical detection. Structured follow-up after the last dose — the phase a clinical pharmacologist would call a washout or discontinuation arm — appears rarely, and where it does appear it is usually for analytical purposes in animals rather than for clinical outcomes in people.

This page summarises what a small set of verified publications reported, and, just as importantly, marks the places where no study in that set looked at all. Nothing here describes a protocol, a taper or a course of action. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision, medication or symptom.

What MK-677 is, in the framing used by the papers

MK-677 is an orally active growth hormone secretagogue: it acts on the ghrelin receptor pathway to stimulate endogenous growth hormone release, rather than supplying growth hormone directly. It is not an approved medicine in the United States; material sold under the name is typically labelled research-use-only, and it is treated as a prohibited substance in regulated sport, which is why several of the available papers come from anti-doping analytical laboratories rather than from clinics.

That regulatory position shapes the evidence. Because the compound never reached approval, there was no post-marketing safety programme, no registry of long-term users, and no requirement to characterise what happens when administration stops. The human data that exist come from investigational trials conducted for specific indications, plus isolated case reports describing people who obtained the compound independently.

The longest randomised human trial: what was measured, and over what window

The most substantial human dataset in this set comes from a randomised, placebo-controlled trial in Alzheimer's disease. Researchers administered MK-677 at 25 mg daily for 12 months and reported that the study found no clinical effect on the progression of Alzheimer's disease compared with placebo, while treatment raised serum insulin-like growth factor 1 (IGF-1) (PMID 19015485). The study's stated endpoints concerned cognitive and functional progression across the treatment year, together with safety monitoring during that year.

What matters for the discontinuation question is the boundary of that design. The reported outcomes describe the treated interval; the publication's scope does not extend to a characterised post-treatment observation phase in which IGF-1, appetite, body weight or glucose handling were tracked back toward baseline after dosing ended (PMID 19015485). Readers looking for a curve showing how quickly IGF-1 returned to pre-treatment values after the last tablet will not find it here, because that curve was not the trial's question.

Why an on-treatment safety profile is not a discontinuation profile

Adverse events recorded while a compound is being administered describe exposure. They do not, by themselves, indicate whether those events persist, resolve, or reverse once exposure ends. A trial can report that a biomarker rose during treatment (PMID 19015485) without establishing the trajectory of that biomarker afterwards. Distinguishing these two things is the central methodological point of any discontinuation discussion.

Adverse Events Around and After Cessation: What Studies Report

A case report of liver injury

A 2025 case report published in BMJ Case Reports described hepatotoxicity attributed to MK-677 in a single individual (PMID 40675653). Case reports of this kind are hypothesis-generating: they document that a clinically significant event occurred in temporal association with use, and they typically include the clinical course after the suspected agent was withdrawn, which is part of how clinicians assess causality. They cannot establish how often such events occur, in whom, or at what exposure, because a single case has no denominator (PMID 40675653).

For someone searching for post-cessation effects, the relevant reading is that at least one published report links MK-677 exposure to organ injury requiring medical attention, and that liver-related presentations can come to attention after, not only during, a period of use. The report does not quantify risk and does not describe a population.

A case report tracking body composition and biomarkers

A 2022 case report in Experimental Physiology documented one individual's self-administration of the selective androgen receptor modulator LGD-4033 together with MK-677, reporting changes in body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content (PMID 36303408). Because two compounds were used concurrently, the report cannot attribute any single change to MK-677 alone, and the authors framed it as a descriptive single-subject observation rather than a controlled experiment (PMID 36303408).

This is the closest thing in the verified set to a longitudinal picture of a person using MK-677 outside a clinic, and it illustrates the limits of that genre: no control condition, no randomisation, no replication, and confounding by the second compound.

Clearance and detection after the last administration

The clearest post-administration data in this set are analytical and come from horses. Researchers reported that MK-0677 was detectable in equine hair following oral administration, establishing hair as a retrospective matrix for identifying past exposure (PMID 36354265). A companion investigation characterised equine metabolism of MK-0677 in vitro and identified the compound and its metabolites in urine and plasma after oral administration, work aimed at selecting reliable markers for doping control (PMID 35302297).

Two cautions apply. First, these are equine data; metabolic pathways, elimination rates and matrix incorporation differ between species, so detection windows do not transfer directly to humans. Second, and more commonly misread, detectability is not the same as biological activity. A metabolite present in hair or urine indicates that exposure occurred; it does not indicate that hormonal effects were ongoing at the time of sampling (PMID 36354265, PMID 35302297).

Animal growth data and the reversibility question

A rodent study examined the effect of the orally active growth hormone secretagogue MK-677 on somatic growth in rats (PMID 30450851). Growth studies in developing animals are informative about the direction of effect during exposure, but they answer a developmental question in a species with a compressed growth timeline. The study's framing concerned growth outcomes during the administration period rather than the trajectory of those outcomes after treatment was withdrawn (PMID 30450851).

Whether soft-tissue or fluid-related changes attributed to growth hormone axis stimulation reverse, persist or partially persist after cessation is a question this verified set does not resolve in any species.

"Rebound": a term used more often in forums than in this literature

Online discussion frequently uses "rebound" to describe a rapid loss of gains, appetite collapse, mood change or hormonal undershoot after a secretagogue is stopped. None of the verified papers used that framework or measured those outcomes. The randomised trial reported on disease progression and IGF-1 during treatment (PMID 19015485); the case reports described an individual clinical presentation and a single-subject biomarker series (PMID 40675653, PMID 36303408); the equine work addressed analytical detection (PMID 36354265).

The honest statement is therefore an absence rather than a reassurance: the verified literature neither documents nor rules out post-cessation rebound phenomena, because no included study set out to measure them.

Evidence-gap map

What a discontinuation study would have to include

Understanding why the gaps persist helps explain what the current record can support. A study capable of describing discontinuation would generally need randomised allocation, a defined exposure period, and then a pre-specified observation window after the last administration with repeated sampling of the outcomes of interest — hormonal, metabolic, functional and symptomatic. It would need a comparator group so that post-cessation drift could be separated from seasonal, training or dietary variation, and enough participants to distinguish signal from noise.

The trial in the verified set had randomisation, placebo control and a 12-month exposure, and it reported that the intervention produced no clinical effect on Alzheimer's disease progression (PMID 19015485), but its reporting frame was the treatment year. Case reports, by construction, cannot supply comparators (PMID 40675653). Until a study is designed around the post-exposure window, statements circulating about what "always" or "never" happens after MK-677 is stopped are extrapolation rather than evidence.

Reading claims about post-cessation effects critically

• Check whether the claim's source measured anything after the last dose. Most MK-677 references describe on-treatment observations only.
• Separate detection from effect. Analytical persistence in hair, urine or plasma reflects exposure history, not ongoing hormonal action (PMID 36354265).
• Note the species. Equine metabolism studies were built for doping control in horses (PMID 35302297), and rodent growth work addresses a developmental model (PMID 30450851).
• Weigh case reports as signals, not rates. One documented instance of hepatotoxicity establishes that the event was observed, not how likely it is (PMID 40675653).
• Watch for combined exposures. Where two compounds were used together, attribution to either alone is not possible (PMID 36303408).

Anyone experiencing symptoms — including fatigue, jaundice, abdominal pain, swelling or changes in blood glucose — during or after any period of exposure to an unapproved compound is in a clinical situation, not an informational one. This page is educational and describes published findings; it does not evaluate individual circumstances and is not a substitute for assessment by a licensed physician.

References

• Hepatotoxicity induced by MK-677 (BMJ Case Reports, 2025)
• LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report (Experimental Physiology, 2022)
• Detection of the growth hormone secretagogue MK-0677 in equine hair following oral administration (Drug Testing and Analysis, 2023)
• Equine metabolism of the growth hormone secretagogue MK-0677 in vitro and in urine and plasma following oral administration (Drug Testing and Analysis, 2022)
• Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats (Yonsei Medical Journal, 2018)
• Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial (Neurology, 2008)